Lttl Review: Prescribed GLP-1s From $79 a Month, and Three Injectables With No Evidence

What is advertised: weight loss plans from $79/month, a microdose plan from $109/month, and tirzepatide described as the most powerful option from $199/month. Up to $140 off a first order, free shipping, and prescription within 48 hours. $79/month is at the low end of this market, and low pricing in compounded GLP-1 telehealth almost always has one of three explanations. Establish which applies before signing up: Dose tiering. The advertised price covers the starting dose only, and rises as you titrate. GLP-1 dosing escalates by design, so this determines what you actually pay by month four. Ask for the full dose-by-dose price schedule in writing. Plan length. Advertised rates in this category are frequently based on a multi-month plan paid up front. Ask what the month-to-month price is and what happens to unused months if you stop. What is included. Whether the consultation fee, syringes and supplies, and follow-up visits are in the price or added. Those three questions are the whole cost picture, and none of them was resolvable from the marketing pages. On the compounded status, which the category consistently underplays: Compounded semaglutide and tirzepatide are not FDA-approved. They are not generic versions of Ozempic, Wegovy, Mounjaro or Zepbound — no generic of any exists — and they have not been shown to be therapeutically equivalent. FDA does not review compounded preparations for safety, effectiveness or manufacturing quality. The published efficacy figures come from trials of the branded drugs at defined doses. They do not automatically transfer to a compounded preparation. Ask which compounding pharmacy is used and whether it is a 503A or 503B facility. A 503B outsourcing facility registers with FDA and is subject to CGMP inspection; a 503A pharmacy compounds per prescription under state board oversight. For an injectable, that distinction is worth knowing. And check the approved products first. LillyDirect and NovoCare Pharmacy now offer manufacturer-direct self-pay pricing, and commercial insurance can reduce it much further. For some patients the approved drug now costs less than the compounded one — a reversal that is not widely understood.

This is where a reader most needs an independent view, because being offered something by a prescribing service reasonably implies it works. For these four, that implication is not supported. Sermorelin — marketed as growth hormone support. A growth hormone releasing hormone analogue. It does increase growth hormone secretion; that part is real. What is not established is that doing so in healthy adults improves body composition, energy or ageing outcomes. Growth hormone therapy in adults without diagnosed deficiency is not supported by evidence and carries real risks: insulin resistance, fluid retention, arthralgia, carpal tunnel syndrome, and theoretical concerns about promoting growth of existing malignancies. Adult growth hormone deficiency is diagnosed by endocrine stimulation testing, not by an online questionnaire. If it is offered without that workup, ask why. NAD+ injectable — marketed for cellular energy. There is no good controlled human evidence that injected NAD+ improves energy, cognition or any ageing outcome. The underlying biology is genuinely interesting and actively researched; the decline of NAD+ with age is real. Interesting biology is not a demonstrated clinical benefit, and infusions commonly cause flushing, nausea and chest discomfort during administration. MIC B12 — marketed for energy and fat metabolism. MIC stands for methionine, inositol and choline, usually combined with vitamin B12, and sold as a "lipotropic" or "fat-burning" injection. This is one of the longest-running weak claims in weight loss medicine. There is no credible controlled evidence that lipotropic injections produce weight loss or fat loss in humans. Vitamin B12 injections genuinely do treat B12 deficiency — which is a specific diagnosis made from a blood test, common in people on metformin, after bariatric surgery, in pernicious anaemia and in strict vegans. If you are deficient, treat the deficiency. If you are not, injecting B12 does not create energy. The "energy" reputation comes almost entirely from the dramatic improvement deficient patients experience. L-carnitine — marketed as fat-to-fuel conversion. Carnitine does transport fatty acids into mitochondria; that is textbook biochemistry. The inference that supplementing it therefore burns fat does not hold, because carnitine is not the rate-limiting step in fat oxidation in healthy people, and trials of carnitine supplementation for weight loss have been small and largely unimpressive. The pattern across all four: a real mechanism, described accurately, followed by an unsupported leap to a clinical benefit. If you are paying for these alongside a GLP-1, you are paying extra for the part with no evidence — and the GLP-1 is doing the work.

On the microdose plan. Sub-therapeutic GLP-1 dosing is marketed for metabolic benefit with fewer side effects. It has no trial evidence. The published outcomes for semaglutide and tirzepatide come from defined escalation schedules to specific maintenance doses. A lower dose is an off-label practice with no outcome data — it will plausibly produce fewer side effects and correspondingly less of the effect. At $109/month against $79/month for the standard plan, it is also not the cheaper option, which is worth noticing. Who should not take a GLP-1 at all: Anyone with a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2. This is a boxed contraindication on the approved products. A history of pancreatitis — requires careful clinical discussion. Type 1 diabetes — these are not a substitute for insulin. Pregnancy, breastfeeding, or planning to conceive. Stop well in advance of a planned pregnancy; discuss timing with a clinician. Severe gastrointestinal disease including gastroparesis. Common side effects: nausea, vomiting, diarrhoea, constipation, abdominal pain, appetite loss, fatigue, injection site reactions — worst during dose escalation, and the most common reason people stop. Serious risks: pancreatitis, gallbladder disease, kidney injury from dehydration secondary to vomiting. Two practical points people are rarely told: Tell any anaesthetist you take a GLP-1 before a procedure. Delayed gastric emptying is clinically relevant to sedation. GLP-1s can affect absorption of oral medicines, including oral contraceptives. Discuss backup contraception with your prescriber. And the one that determines the real cost: weight regain after stopping is the norm, not the exception, in the published follow-up data. This is long-term treatment for a chronic condition, so evaluate it as a long-term cost rather than a three-month project.

How much does Lttl cost? Advertised from $79/month for weight loss, $109/month for microdose plans and $199/month for tirzepatide, with up to $140 off a first order and free shipping. Ask whether the price rises with dose and whether rates assume a prepaid plan. How fast is it? The company states prescription and shipping within 48 hours after a free two-minute assessment reviewed by a licensed clinician. Are the medications FDA-approved? No. They are compounded. Compounded preparations are not reviewed by FDA for safety, effectiveness or manufacturing quality, are not generics, and have not been shown to be therapeutically equivalent to the branded drugs. Is microdosing a good idea? It has no trial evidence. Published outcomes come from defined escalation to specific maintenance doses. It is also priced above the standard plan here. Is sermorelin worth it? Not for adults without diagnosed growth hormone deficiency, which requires endocrine stimulation testing rather than a questionnaire. Do NAD+ injections work? There is no good controlled human evidence for the benefits they are marketed for. What about MIC B12 or lipotropic injections? No credible controlled evidence for weight or fat loss. B12 injections treat diagnosed deficiency — test first. Does L-carnitine burn fat? The biochemistry is real; the weight loss inference is not supported by trials. Who should not use GLP-1s? Anyone with a personal or family history of medullary thyroid carcinoma or MEN2, and anyone pregnant, breastfeeding or planning pregnancy, among others. Discuss with a clinician. Will I keep the weight off? Regain after stopping is the norm in published follow-up. Plan for long-term treatment and long-term cost.